Alterity Therapeutics Limited (NASDAQ:ATHE – Get Free Report) saw a large increase in short interest during the month of June. As of June 15th, there was short interest totalling 22,500 shares, an increase of 8.2% from the May 31st total of 20,800 shares. Based on an average trading volume of 73,900 shares, the short-interest ratio is currently 0.3 days. Approximately 0.3% of the company’s stock are sold short.
Alterity Therapeutics Trading Down 1.1 %
NASDAQ:ATHE traded down $0.02 during trading hours on Tuesday, reaching $1.78. The company had a trading volume of 3,139 shares, compared to its average volume of 57,645. Alterity Therapeutics has a 52 week low of $1.55 and a 52 week high of $5.41. The firm’s 50 day moving average price is $1.97 and its 200-day moving average price is $2.03.
Wall Street Analysts Forecast Growth
Separately, Benchmark reaffirmed a “speculative buy” rating and issued a $4.00 target price on shares of Alterity Therapeutics in a research report on Thursday, March 7th.
About Alterity Therapeutics
Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that is in Phase I clinical trial for the treatment of Parkinson's disease.
Featured Articles
- Five stocks we like better than Alterity Therapeutics
- 3 Warren Buffett Stocks to Buy Now
- RXO Shares Surge Following New Acquisition Deal
- REIT Stocks – Best REIT Stocks to Add to Your Portfolio Today
- 3 Stock Dips Insiders Are Buying: Vestis, Shenandoah, Treace
- Biggest Stock Losers – Today’s Biggest Percentage Decliners
- Biotech Stock Breakout: IBB Eyes Resistance with Amgen and Vertex
Receive News & Ratings for Alterity Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alterity Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.